GAGabriela Silva Arcanjo

Gabriela Silva Arcanjo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Gabriela Silva Arcanjo has a total of 75 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Differential Diagnosis of Mucopolysaccharidoses Types I, II , III , IVA , and VI Through Analysis of Leukocytic Inclusions

    by Márcio A. W. Melo, Marcelo S. Kertenetzky, Cristina M. Silveira, Maíra M. Ribeiro, Paula F. Medeiros, Gabriela S. Arcanjo

    Mucopolysaccharidoses (MPS) are lysosomal storage disorders characterized by the accumulation of glycosaminoglycans (GAGs), which can lead to cytoplasmic alterations in leukocytes. The objective of this study was to characterize leukocyte inclusions in patients with different types of MPS and assess their diagnostic relevance. A total of 69 Brazilian patients diagnosed with five MPS types were evaluated through cytological analysis of peripheral blood smears. Distinct leukocyte inclusion patterns were observed in four subtypes. In MPS Type II, small violet cytoplasmic inclusions were present in lymphocytes. In MPS Type III, larger violet inclusions were identified in lymphocytes. Patients with MPS Type IVA showed large, sparse granulations in neutrophils, while those with MPS Type VI exhibited coarse inclusions in all leukocytes, characteristic of the Alder–Reilly anomaly. No leukocyte inclusions were found in MPS Type I. These observations demonstrate that leukocyte inclusions vary according to MPS subtype and may represent a useful auxiliary cytological finding. Their identification may support diagnostic suspicion and contribute to the differential diagnosis of MPS II, III, IVA, and VI, complementing enzymatic and biochemical testing.

  • Open Access

    Giant Elliptical Platelets as a Cytological Component in MYH9 ‐Related Disease

    by Márcio Antonio W. Melo, Cristina M. Silveira, Maíra M. Ribeiro, Evilly R. O. Magalhães, Gabriela S. Arcanjo

  • Open Access

    A genetic risk score based on BCL11A and HBS1L‐MYB variants predicts clinical severity in Brazilian sickle cell anaemia patients

    by Gabriela S. Arcanjo, Alexsandro P. Silva, Madi V. Diniz, Igor F. Domingos, Diego A. Pereira‐Martins, Amanda B. Araújo, Talita S. S. França, Ana C. Anjos, Aderson S. Araujo, Edis Belini‐Junior, et al.

    Summary: Individuals with sickle cell anaemia (SCA) exhibit significant clinical heterogeneity influenced by several factors, especially fetal haemoglobin (HbF) levels. Variations in adult HbF levels are partly explained by the co‐inheritance of genetic variants that regulate globin expression. In this study, we investigated the association of BCL11A rs4671393, rs1427407, rs11886868 and HBS1L‐MYB rs9399137 polymorphisms with HbF levels and clinical complications in a cohort of 409 adult Brazilian SCA patients. Our findings reveal that variant alleles of all four single‐nucleotide polymorphisms (SNPs) were significantly associated with higher HbF levels. Moreover, homozygosity for the major alleles was independently associated with higher risk and cumulative incidence of stroke, avascular necrosis, leg ulcers, priapism and acute chest syndrome. Haplotype analysis with BCL11A variants was also associated with HbF and the patient's phenotype. A genetic risk score (GRS) combining the risk genotypes was significantly associated with lower HbF levels ( p < 0.0001) and increased complication risk ( p < 0.0001). A model integrating the GRS with clinical variables demonstrated superior discriminatory performance (area under the curve (AUC): 0.72) compared to models based solely on clinical factors. In summary, this study underscores the clinical relevance of HbF‐related genetic variants and supports their integration into risk stratification and personalized management strategies for SCA.


  • Open Access

    Crossed Erythrocytes Agglutination Pattern Observed in a Patient With Hereditary Elliptocytosis

    by Márcio A. W. Melo, Cristina M. Silveira, Maíra M. Ribeiro, Gabriela S. Arcanjo

  • Vitamin D receptor gene polymorphisms and 25-hydroxyvitamin D levels: association with cerebrovascular disease in sickle cell anemia

    by Gabriela S. Arcanjo, Jéssica V. G. F. Batista, Jéssica M. F. Oliveira, Igor F. Domingos, Thais H. C. Batista, Diego A. Pereira-Martins, Betânia L. D. Hatzlhofer, Amanda B. S. Araújo, Talita S. S. França, Ana C. M. Anjos, et al.

    Sickle cell anemia (SCA) is associated with a high prevalence of cerebrovascular complications, such as ischemic stroke, particularly at young ages. Among various molecules, vitamin D has been implicated in stroke occurrence. By binding to the vitamin D receptor (VDR), vitamin D regulates several mechanisms, potentially influencing pathways involved in the pathophysiology of cerebral vasculopathy. Here, we evaluated the association between VDR gene polymorphisms and 25-hydroxyvitamin D (25(OH)D) levels with CVD in a cohort of patients with SCA. The frequency of CVD and laboratory data were retrospectively obtained from the medical records. Genotyping for the functional FokI (rs2228570) and Cdx-2 (rs11568820) VDR polymorphisms was performed in 459 unrelated SCA patients. 25(OH)D levels were measured in a subset of 45 patients. The TT genotype of the FokI VDR polymorphism was associated with a higher frequency (OR: 2.82; 95% CI: 1.38-5.76, p = 0.006) and higher cumulative incidence (34% vs 16%, p = 0.001) of CVD compared to the other genotypes. Among patients under hydroxyurea (HU) therapy, individuals with the TT-FokI genotype (median: 13.9 ng/mL) had lower 25(OH)D levels compared to those with CC/CT genotypes (median: 20.2 ng/mL; p = 0.033). Similarly, patients with CVD and the TT-FokI genotype (median: 12.3 ng/mL) had reduced 25(OH)D levels compared to CC/CT carriers (median: 20.8 ng/mL; p = 0.034). These findings suggest that the FokI VDR polymorphism may serve as a potential genetic modulator of cerebrovascular complications in individuals with SCA.

  • Open Access

    Inflammatory cytokine profile in patients with sickle cell anaemia and leg ulcers

    by M. V. Diniz, A. P. Silva, G. S. Arcanjo, T. H. C. Batista, J. V. S. Rodrigues, M. J. B. M. Rêgo, H. I. Leão, R. C. Silva, F. O. Souto, C. M. L. Melo, et al.


  • BMP6 and VDR gene polymorphisms are associated with osteonecrosis in a sickle cell anaemia cohort

    by Gabriela S. Arcanjo, Mariana B. Souza, Igor F. Domingos, Diego A. Pereira‐Martins, Diego A. Falcão, Jessica V. Batista, Betania L. Hatzlhofer, Madi V. Diniz, Alexsandro P. Silva, Werbson L. Guaraná, et al.

    Summary: The occurrence and severity of osteonecrosis in sickle cell anaemia (SCA) vary due to risk factors, including genetic modifiers. Bone morphogenetic proteins (BMPs), particularly BMP6, and the vitamin D receptor (VDR) play key roles in cartilage and bone metabolism, making them potential contributors to orthopaedic outcomes in SCA. Here, we evaluated the association of polymorphisms in BMP6 (rs3812163, rs270393 and rs449853) and VDR (FokI rs2228570 and Cdx2 rs11568820) genes with osteonecrosis risk in a Brazilian SCA cohort. A total of 177 unrelated SCA patients were selected. The AA genotype of BMP6 rs3812163 was independently associated with a lower osteonecrosis risk (p = 0.015; odds ratio (OR): 0.38; 95% confidence interval (CI): 0.18–0.83) and with the long‐term cumulative incidence of osteonecrosis (p = 0.029; hazard ratio: 0.56, 95% CI: 0.34–0.94). The VDR rs2228570 TT genotype was independently associated with a lower osteonecrosis risk (p = 0.039; OR: 0.14; 95% CI: 0.02–0.90). In summary, our results provide evidence that BMP6 rs3812163 and the VDR rs2228570 might be implicated in osteonecrosis pathophysiology in SCA and might help identify individuals at high risk.


  • Open Access

    Functional characterization of compound heterozygosity Hb S/Hb Deer Lodge in Brazil

    by Marcondes J. Sobreira, Thais H. Batista, Rodrigo M. Santana, Gabriela S. Arcanjo, Susan E. Jorge, Magnun N. Santos, Dulcinéia M. Albuquerque, Betânia L. Hatzlhofer, Ana C. dos Anjos, Fernando F. Costa, et al.

  • Polymorphisms and gene expression of metalloproteinases and their inhibitors associated with cerebral ischemic stroke in young patients with sickle cell anemia

    by Ó. Do Kleyton Palmeira, Ana Karla da Silva Freire, Débora Nascimento de Nóbrega, Roberta dos Santos Souza, Isabela Cristina Cordeiro Farias, Taciana Furtado de Mendonça Belmont, Andreia Soares da Silva, Gabriela da Silva Arcanjo, Aderson da Silva Araujo, Ana Cláudia Mendonça dos Anjos, et al.

    Background Sickle cell anemia (SCA) is a genetic disease with great clinical heterogeneity and few viable strategies for treatment; hydroxyurea (HU) is the only widely used drug. Thus, the study of single nucleotide polymorphisms (SNPs) and the gene expression of MMPs 1, 2, 9, 7 and TIMPs 1 and 2, which are involved in the regulation of extracellular matrix, inflammation, and neuropathies, may provide further insights into the pathophysiology of the disease and elucidate biomarkers and molecules as potential therapeutic targets for patients with SCA. Methods and results We evaluated 251 young individuals with SCA from northeastern Brazil. The groups were divided according to vaso-occlusive crisis (VOC) and cerebrovascular disease (CVD), compared to control individuals. SNP detection and gene expression assays were performed by real-time PCR, TaqMan system®. Both the expression levels of MMP1 gene, and the SNP MMP1-1607 1G/2G were associated with the risk of cerebral ischemic stroke (IS), and the expression of MMP1 was also associated with a higher frequency of VOC/year. Expression levels of MMP7, TIMP1, and TIMP2 were increased in patients conditioned to IS. The SNP 372T>C (rs4898) TIMP1 T alleles were more frequent in patients with > 5 VOC events/year. The SNP rs17576 of MMP9 showed differences in gene expression levels; it was increased in the genotypes AG, and AG+GG. Conclusion The findings of this study, the SNPs, and expression provide initial support for understanding the role of MMPs-TIMPs in the pathophysiology of SCA in young patients.


  • Open Access

    Gasser cell: A biomarker of response to enzyme replacement therapy in patients with mucopolysaccharidosis type VI

    by Márcio Antonio Wanderley de Melo, Marcelo Soares Kertenetzky, Cristina Magalhães da Silveira, Maíra Magalhães Ribeiro, Gabriela da Silva Arcanjo, Antônio Roberto Lucena-Araújo, Marcos André Cavalcanti Bezerra, Maria Tereza Cartaxo Muniz, Maria Do Socorro de Mendonça Cavalcanti

    The mucopolysaccharidosis (MPS) type VI is a rare lysosomal storage disease presenting leukocyte inclusions (Alder-Reilly anomaly) and lymphocytes with metachromatic inclusion surrounded by clear spaces, Gasser cells. Currently, an enzyme replacement therapy (ERT) with galsulfase is used to treat MPS type VI. This study evaluated 14 patients with MPS type VI performed cell counts Gasser before and after six months from the beginning of ERT. It was observed an average of 12.7% cells per patient, and after six months was found complete cell Gasser disappearance, proving to be an effective biomarker of response to ERT.